Treatment outcome among HIV-TB coinfected patients treated with single dose Dolutegravir 50mg and rifampicin-based therapy in a single centre in Bayelsa, Nigeria

shorter regimens, and 7 (13,2%) -with longer regimens (p < 0.05).Treatment outcomes were not evaluated in 6 patients (10,3%) who had started on shorter regimens and in 9 (17.0%)-on longer regimens (p > 0.05).One patient (1,7%) in the short regimen group died of TB and 2 (3.8%) in the long regimen groups.Four patients treated with shorter regimens (6.9%) and 4 (7,5%) patients treated with longer regimens had other than TB causes of death (p > 0,05).One (1.7%) patient treated with shorter regimen and 2 (3.8%) -with longer regimens were reported as lost to follow up, and 4 (7.5%)patients stay on treatment with long regimens.The prognostic factor for ineffective treatment with long regimens was pre-XDR-TB (OR -7.4,95%; CI 1.2 -46.5, p = 0.03) Discussion: a significant difference was found for the therapy outcomes "effective" and "ineffective" treatment between the two comparison groups (p < 0.05).All-oral shorter regimens increased treatment efficiency by 1.6 times, reduced the chance of ineffective treatment by more than 3.The new all-oral shorter regimens will bring us closer to the MDR-TB treatment efficacy target for the European Region (WHO, 2021).Conclusion: introduction of new all-oral shorter regimens into clinical practice will increase the efficiency of therapy by 30% and reduce the number of "ineffective treatment" cases by 10%.